Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.gianpathlabs.com | |
Market Cap | 24.72 Cr. | |
Enterprise Value(EV) | 21.84 Cr. | 2022-03 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 4.23 | Trailing Twelve Months Ending 2022-03 |
Price-Earning Ratio (PE) | 5.64 | Trailing Twelve Months Ending 2022-03 |
Industry PE | 47.03 | Trailing Twelve Months Ending 2022-03 |
Book Value / Share | 13.56 | Trailing Twelve Months Ending 2022-03 |
Price to Book Value | 1.76 | Calculated using Price: 23.85 |
Dividend Yield | 0.00 | Period Ending 2022-03 |
No. of Shares Subscribed | 1.03 Cr. | 10,341,527 Shares |
FaceValue | 10 | |
Company Profile | ||
The company is engaged in the business of providing diagnostic and related healthcare services. The company provides a wide range of diagnostic tests and services like patient diagnosis services, prevention, and wellness diagnosis services to patients and healthcare providers. The company caters to individual patients, hospitals, corporates and other healthcare providers. The company offers various tests including biochemistry, clinical pathology, coagulation, cytogenetics, cytology, hematology, histopathology, immunoassay, microbiology, molecular biology, and radiology services. |
1 Day |
|
-2.45% |
1 Week |
|
-3.25% |
1 Month |
|
+7.19% |
3 Month |
|
+13.57% |
6 Month |
|
-34.30% |
1 Year |
|
-48.38% |
2 Year |
|
+115.06% |
5 Year |
|
|
10 Year |
|
1 years | 2022-03 | |
Return on Equity (%) | 31.16 | |
Return on Capital Employed (%) | 44.24 | |
Return on Assets (%) | 18.95 |
Particulars | 1 years | 2022-03 Rs. Cr. |
Shh. Funds | 14 | |
Non Curr. Liab. | 2 | |
Curr. Liab. | 7 | |
Minority Int. | ||
Equity & Liab. | 23 | |
Non Curr. Assets | 13 | |
Curr. Assets | 10 | |
Misc. Exp. not W/O | ||
Total Assets | 23 |
Particulars | 1 years | 2022-03 Rs. Cr. |
Net Sales | 16 | |
Other Income | 1 | |
Total Income | 16 | |
Total Expenditure | -9 | |
PBIDT | 7 | |
Interest | -1 | |
Depreciation | 0 | |
Taxation | -1 | |
Exceptional Items | ||
PAT | 4 | |
Minority Interest | ||
Share Associate | ||
Other Related Items | ||
Consolidated Net Profit | 4 | |
Adjusted EPS | 4 |
Particulars | 1 years | 2022-03 Rs. Cr. |
Cash Fr. Operatn. | 6 | |
Cash Fr. Inv. | -4 | |
Cash Fr. Finan. | 1 | |
Net Change | 2 | |
Cash & Cash Eqvt | 5 |
Sat, 21 Jan 2023
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 Dear Sir/Madam We enclose herewith the Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations 2018 for the period ended December 31 2022 for your information and record.Thanking You Yours faithfully For GIAN LIFE CARE LIMITED |
Mon, 14 Nov 2022
Board Meeting Outcome for Outcome Of Board Meeting Held On Monday November 14 2022 Pursuant to the provisions of Regulation 30 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we are pleased to inform you that the Board of Directors at their meeting held today i.e. 14th November 2022 has inter-alia considered and approved the following:-1. Standalone and Consolidated Financial Results of the Company for the half year ended 30th September 2022. (Signed Copy along with Limited Review Report enclosed). The Board Meeting commenced at 06:00 P.M and concluded at 07.50 P.M.The above information shall also be made available on the website of the Company at https://gianlifecare.org.You are requested to kindly take the above information in your records.Thanking You Yours faithfully For GIAN LIFE CARE LIMITED |
Mon, 14 Nov 2022
Standalone And Consolidated Financial Results Of The Company For The Half Year Ended 30Th September 2022 Pursuant to the provisions of Regulation 30 and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 we are pleased to inform you that the Board of Directors at their meeting held today i.e. 14th November 2022 has inter-alia considered and approved the following:-1. Standalone and Consolidated Financial Results of the Company for the half year ended 30th September 2022. (Signed Copy along with Limited Review Report enclosed). The Board Meeting commenced at 06:00 P.M and concluded at 07.50 P.M.The above information shall also be made available on the website of the Company at https://gianlifecare.org.You are requested to kindly take the above information in your records. |
Fri, 27 Jan 2023 |
|
|
|
|
|